Clinical trials have shown that blocking cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) could improve overall survival (OS) in advanced melanoma, which were first respectively approved by the US Food and Drug Administration (FDA) in 2011 and 2014 [2, 3]. This evidence concerns the gene PDCD1 and melanoma.